Abstract

Malapposition is a common finding in stent and scaffold thrombosis (ScT). Evidence from studies with prospective follow-up, however, is scarce. We hypothesized that incidental observations of strut malapposition might be predictive of late ScT during subsequent follow-up. One hundred ninety-seven patients were enrolled in a multicentre registry with prospective follow-up. Optical coherence tomography (OCT), performed in an elective setting, was available in all at 353 (0–376) days after bioresorbable scaffold (BRS) implantation. Forty-four patients showed evidence of malapposition that was deemed not worthy of intervention. Malapposition was not associated with any clinical or procedural parameter except for a higher implantation pressure (p = 0.0008). OCT revealed that malapposition was associated with larger vessel size, less eccentricity (all p < 0.01), and a tendency for more uncovered struts (p = 0.06). Late or very late ScT was recorded in seven of these patients 293 (38–579) days after OCT. OCT-diagnosed malapposition was a predictor of late and very late scaffold thrombosis (p < 0.001) that was independent of the timing of diagnosis. We provide evidence that an incidental finding of malapposition—regardless of the timing of diagnosis of the malapposition—during an elective exam is a predictor of late and very late ScT. Our data provide a rationale to consider prolonged dual antiplatelet therapy if strut malapposition is observed.

Highlights

  • Bioresorbable scaffolds (BRS) were introduced to offer transient vessel support after coronary angioplasty while avoiding long-term risks associated with permanent metallic stents [1]

  • Patients had undergone elective Optical coherence tomography (OCT) at the end of the implantation procedure, during non-target vessel-staged procedures, or in the setting of elective invasive exams. In none of these patients was there evidence of ischemia in the region perfused by the vessel treated with bioresorbable scaffold (BRS) and OCTs had been performed as elective controls after implantation of these novel devices

  • A total of 197 patients (219 lesions) who underwent elective OCT within 353 (0–376) days after BRS implantation were enrolled in the study (Table 1)

Read more

Summary

Introduction

Bioresorbable scaffolds (BRS) were introduced to offer transient vessel support after coronary angioplasty while avoiding long-term risks associated with permanent metallic stents [1]. Studies based on quantitative coronary angiography provided evidence that undersizing (i.e., choice of a BRS smaller than the reference vessel) is strongly associated with late adverse events [8,9]. While the mechanistic rationale for the association of malapposition and late stent/scaffold thrombosis is solid [10,11], evidence to date is limited to observational studies in which malapposition was frequently found in cases of ScT [12,13,14,15,16].

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.